Dr. Klemens Schulz appointed CPO of the L&R Corporate Group
mehr
Storys zum Thema Pharmaindustrie
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Sysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
mehrB. Braun Medical acquires Dismed's hand sanitizer and intravenous fluid businesses in South Africa / Commitment to growth and local manufacturing for the African healthcare sector
Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
mehrEckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
mehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehr
CGC - Cramer-PR im Gesundheitswesen
CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
Weinheim/Germany (ots) - International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children. UCD is a life-threatening ...
mehrNew UK sales subsidiary for Dr. Hauschka: WALA UK Ltd.
Bad Boll/Eckwälden (ots) - Dr. Hauschka, a brand marketed by the traditional German company WALA Heilmittel GmbH, is now able to boost its presence on the UK market. A newly established subsidiary, WALA UK Ltd., which is based in Oxfordshire near London, will be marketing and distributing the premium natural and organic cosmetics products as of 1 January. Dr. Hauschka enthusiasts will be able to find a wide range of ...
mehrFresenius achieves record Q3 earnings - improves 2011 earnings outlook
Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...
Ein DokumentmehrPrehospital Thrombolysis for AMI to be Studied in New Clinical Trial / Study will investigate concept that prehospital lysis can be at least as good as primary PCI
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
mehrGirindus AG - Oligonucleotide Production Expansion Accelerated
Bensberg (ots) - Girindus, with core competencies in process development, scale up and manufacture of innovative drug and cosmetic actives, sees a significant increase in demand for its commercial oligonucleotide production capabilities in the USA and Europe. "Our know-how and our technical expertise in the area of oligonucleotide research, development and manufacturing has been validated by an increased market ...
mehrFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG reports Fourth Quarter and Full Year Results 2003
Bad Homburg, Germany (ots) - Summary Full Year 2003: Company met or exceeded financial targets for 2003 and will propose 7th consecutive dividend increase Net Revenues $ 5,528 million + 9% Operating income (EBIT) $ 757 million + 9% Net income $ 331 million + 14% Operating Cash Flow $ ...
mehr
Fresenius announces results of Financial Year 2002
Bad Homburg (ots) - - Sales: + 3 % to Euro 7.5 billion currency-adjusted: + 9 % - EBIT: + 10 %* to Euro 837 million - Net income: + 44 %* to Euro 134 million - Dividend: + 10 % to Euro 1.14 per ordinary share and Euro 1.17 per preference share The Fresenius health care group increased sales in the 2002 financial year by a plus ...
mehr
Vorherige123456